Neonatal Diabetes Mellitus Due to KCNJ11 (KIR6.2) Mutation Successfully Treated with Sulfonylurea [PDF]
Neonatal Medicine, 2021 Neonatal diabetes mellitus (NDM) is a rare disease that occurs at less than 6 months of age and is presumably caused by a mutation in the gene that affects pancreatic beta-cell function. Approximately 80% of NDM cases reveal a known genetic mutation, and
Sehun Jang +5 more
doaj +1 more source
Risk of new-onset prostate cancer for Metformin versus Sulfonylurea use in Type 2 Diabetes Mellitus: A propensity score-matched study [PDF]
, 2022 The aim of this study was to compare the risks of new-onset prostate cancer between metformin and sulfonylurea users with type 2 diabetes mellitus (T2DM).
Liu, Xuejin +14 more
core +2 more sources
Molecules, 2022 Chlrosulfuron, a classical sulfonylurea herbicide that exhibits good safety for wheat but causes a certain degree of damage to subsequent corn in a wheat–corn rotation mode, has been suspended field application in China since 2014.
Lei Wu +5 more
doaj +1 more source
De novo HNF1A mutation of young maturity-onset diabetes 3 of a young girl—Case report
BMC Endocrine Disorders, 2023 Young maturity-onset diabetes of the young type3(MODY3) as a special type of diabetes, the probability of diagnosis is low. This article reports on a case and reviews the relevant knowledge of the disease. We report an 11-year-and-11-month-old girl whose
Haoran Peng, Jianbo Li, Zhang Wang
doaj +1 more source
Synthesis of sulfonylurea derivatives and their α-glucosidase inhibitory activity
Vietnam Journal of Science, Technology and Engineering, 2022 The paper describes the preparation of new sulfonylurea derivatives from sulfonyl carbamate 6 with amino derivatives. The process for synthesis of the key compound 6 included three steps starting from compound 6-chloronicotinic acid 1, which are readily
Thi Thoi Bui +2 more
doaj +1 more source
Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study [PDF]
Diabetes & Metabolism Journal, 2020 BackgroundThere is limited information regarding the optimal third-line therapy for managing type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy.
Jeong Mi Kim +12 more
doaj +1 more source
Сахарный диабет, 2022 BACKGRAUND: Now the trend of Type 2 Diabetes Mellitus (T2DM) management from glucocentric to cardioprotective approach take place, and it especially relevant for the multiple group of patients with T2DM using Sulphonylurea (SU).
N. A. Chernikova +3 more
doaj +1 more source
Bioequivalence assessment of the two brands of glimepiride tablets [PDF]
Vojnosanitetski Pregled, 2006 Background/Aim. Glimepiride, as an antidiabetic from the group of sulfonylurea, is administered perorally in the treatment of diabetes mellitus. The aim of this study was to compare pharmacokinetic profiles and relative bioavailabilities of the two oral ...
Jovanović Dušan +4 more
doaj +1 more source
Journal of Lipid and Atherosclerosis, 2022 Objective Recent studies have raised concerns about the cardiovascular safety of dipeptidyl peptidase-4 (DPP4) inhibitors. We performed a systematic review and meta-analysis to compare the cardiovascular outcomes of sulfonylureas (SUs) versus DPP4 ...
Won Kyeong Jeon +3 more
doaj +1 more source
Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial [PDF]
Diabetes & Metabolism Journal, 2019 BackgroundMetformin, sulfonylurea, and dietary fiber are known to affect gut microbiota in patients with type 2 diabetes mellitus (T2DM). This open and single-arm pilot trial investigated the effects of the additional use of fiber on glycemic parameters,
Seung-Eun Lee +7 more
doaj +1 more source